BrainsWay Ltd. - ADR

Name: BrainsWay Ltd. - ADR Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: BrainsWay Ltd. - ADR

Stock Card

$14.52

$0.22 (1.54%)

As on 31-Aug-2026 16:00EDT

Market cap

$575 Mln

Revenue (TTM)

$61 Mln

P/E Ratio

62.2

P/B Ratio

7.3

Div. Yield

0 %

BrainsWay - ADR Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 14.19 High: 14.67

52 Week Range

Low: 3.57 High: 17.40

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

0.1 %
ROCE

-- %
Industry P/E

44.46
EV/EBITDA

44.1
Debt to Equity

0
Book Value

$--
EPS

$0.4
Face value

--
Shares outstanding

40,188,959

10 Years Aggregate

CFO

$-34.26 Mln

EBITDA

$-49.00 Mln

Net Profit

$-66.28 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
BrainsWay - ADR	205.4	-4.8	-8.6	273.3	160.9	48.8	--
BSE Sensex^*	-9.1	-1.5	2.9	-3.6	5.9	6.0	10.5
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 31-Aug-2026 | *As on 01-Sep-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022	2021	2020
BrainsWay - ADR	101.7	45.1	162.3	-67.9	2.1	-22.7
S&P Small-Cap 600	4.0	7.0	13.9	-17.4	25.3	9.6
BSE Sensex	9.1	8.1	18.7	4.4	22.0	15.8

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
BrainsWay - ADR	14.5	574.7	61.0	9.6	17.2	12.5	62.2	7.3
10X Genomics Inc (TXG)	62.5	8,018.1	616.9	-75.1	1.7	-9.3	--	10.2
Avantor (AVTR)	14.5	9,638.1	6,561.1	-578.0	-4.5	-10.3	--	1.7
Bio-Rad Laboratories	365.1	9,761.6	2,589.3	222.4	-6.0	3	44.5	1.3
Bruker (BRKR)	58.0	8,696.7	3,499.6	-71.2	0.5	-3.2	--	3.8
Glaukos Corp (GKOS)	179.6	10,905.5	612.8	-188.1	-30.6	-28.1	--	16.4
Lantheus Holdings (LNTH)	101.0	6,577.5	1,556.3	275.3	24.6	22.9	24.1	5.0
Merit Medical Systems (MMSI)	90.7	5,403.2	1,579.2	145.6	14.3	8.9	37.2	3.2
Penumbra (PEN)	323.1	12,752.7	1,504.9	160.6	13.6	10.9	79.4	8.4
Repligen (RGEN)	181.0	9,947.9	785.1	41.5	9.9	2	251.8	4.9

Shareholding Pattern

View Details

About BrainsWay - ADR

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive... disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel. Read more

Chief Executive Officer

Mr. Hadar Levy
Chief Executive Officer

Mr. Hadar Levy
Headquarters

Jerusalem
Website

https://www.brainsway.com

FAQs for BrainsWay - ADR

What is the current share price of BrainsWay Ltd - ADR Today?

The share price of BrainsWay Ltd - ADR is $14.52 (NASDAQ) as of 31-Aug-2026 16:00 EDT. BrainsWay Ltd - ADR has given a return of 160.91% in the last 3 years.

What is the current PB & PE ratio of BrainsWay Ltd - ADR?

The P/E ratio of BrainsWay Ltd - ADR is 62.17 times as on 28-Aug-2026, a 40 premium to its peers’ median range of 44.46 times.
The P/B ratio of BrainsWay Ltd - ADR is 7.31 times as on 28-Aug-2026, a 93 premium to its peers’ median range of 3.79 times.

PE & PB ratio at the end of financial year.